Management of Cytokine Release Syndrome (CRS) and HLH-Reference-Cited by-同舟云学术

Management of Cytokine Release Syndrome (CRS) and HLH

Published:2022 Issue: Volume: Page:135-139
ISSN:
Container-title:The EBMT/EHA CAR-T Cell Handbook
language:
Short-container-title:

Author:

Ayuketang Francis Ayuk,Jäger Ulrich

Abstract

AbstractCytokine release syndrome (CRS) is caused by a rapid and mild to massive release of cytokines from immune cells involved in immune reactions, particularly after immunotherapy. The frequency and severity of CRS after CAR-T cell therapy varies between products (any grade: 37–93%, G3/4: 1–23%) (Neelapu et al. 2017; Schuster et al. 2019; Abramson et al. 2020).

Funder

European Society for Blood and Marrow Transplantation

The European Hematology Association

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-030-94353-0_26

Reference12 articles.

1. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52.

2. Caimi PF, Sharma A, Rojas P, et al. CAR-T therapy for lymphoma with prophylactic tocilizumab: decreased rates of severe cytokine release syndrome without excessive neurologic toxicity. Blood. 2020;136:30–1. https://ash.confex.com/ash/2020/webprogram/Paper143114.html

3. Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019;58(1):5–17.

4. Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR-T cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134(24):2149–58.

5. Kadauke S, Myers RM, Li Y, et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J Clin Oncol. 2021;39(8):920–30.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement;Expert Opinion on Biological Therapy;2024-09

2. The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs;Pharmacological Research;2024-05

3. cytokine release syndrome;Radiopaedia.org;2024-04-19

4. Targeting CD19 for the treatment of autoimmune with a novel T cell engager;2024-02-22

5. Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy;Frontiers in Medicine;2024-01-03